Feature | July 17, 2012| Dave Fornell

An Introduction to Atherectomy Systems

The Bayer-Medrad Navitus atherectomy catheter has two cutting surfaces and integrated aspiration.

Atherectomy devices are used in the cath lab to debulk lesions by cutting or laser ablating plaque, calcium and tissue hyperplasia from vessel walls, allowing recanalization of the vessel lumen as an end in itself, or in preparation for stenting. While some devices have an indication for the coronaries, the primary use of these devices is for peripheral artery disease (PAD) in the legs. 

Healthcare providers are increasingly viewing PAD as a progressive, chronic disease that requires a continuum of treatment, where few patients are treated only once.  Many are treated to restore flow whenever the disease re-occludes a vessel, or a new vessel develops a blockage.  The goal is to improve quality of life and prevent amputation. 

Treatments that restore bloodflow without reducing the ability to treat the vessel in the future are better suited for PAD.  Atherectomy is seen by many as an ideal therapy for PAD because it can restore flow while removing the plaque burden and does not leave behind a permanent obstacle to future treatments, such as a stent. Stenting in the legs leads to frequent restenosis or fractured stent struts, and can be problematic or prevent repeat interventional or open surgical repairs.

Cost of treatment is always a concern for both reimbursement and institutions. Atherectomy may be a less costly approach to PAD over the life of a patient than open surgery or ballooning and stenting.  Within the atherectomy market, the vendors must demonstrate both economic advantages and procedural success. The total cost (including the number) of devices needed for a procedure, the duration of lumen patency and reduction of side effects that require additional treatments influence use of these technologies.

Cardiovascular Systems Inc. (CSI) recently shared 12-month data from the COMPLIANCE 360° study of severely calcified above-the-knee lesions. The prospective study of 50 patients (with 65 lesions) at nine U.S. sites randomized patients equally to balloon angioplasty alone versus the Diamondback Orbital Atherectomy System with adjunctive ballooning.  The study showed that avoiding stents and reducing restenosis saved money. The approximate incremental cost savings of the atherectomy group at six months was $5,264 per additional acute adjunctive stenting or restenosis avoided.  The study also found the angioplasty arm required bailout stenting in 84 percent of the procedures to achieve results equivalent to the Diamondback arm. 

There is increasing interest in atherectomy treatments in vessels below the knee. Successfully recanalizing arteries to the ankle and foot can reduce pain, restore mobility and reverse ulceration, which may have a major impact on the costs of chronic wound care in lower extremities.

There was a setback for coronary atherectomy with the results of the ROTAXUS (A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions) trial, presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) symposium. The trial found the process was not superior to standard balloon angioplasty and decreased the efficacy of the stent in reducing new tissue growth within the blood vessel.

Drug-eluting stents (DES) are liberally used in complex lesions. Heavily calcified stenoses have not been adequately studied, and form a challenge for immediate and late outcomes. Rotational atherectomy has been shown to effectively modify calcified plaques and facilitate stent delivery and expansion. In patients with complex calcified lesions, rotablation followed by DES seems a rational combination, but there was a lack of evidence prior to the ROTAXUS trial. 

 

Comparing Scanners 

This article served as an introduction to an atherectomy system comparison chart in the July-August 2012 print issue of DAIC. The chart can be accessed in the comparison chart tab at the top of the screen, or at www.dicardiology.com/comparison-charts?t=Atherectomy+Systems  The chart included the following vendors: 

 

Bayer HealthCare (Medrad) - www.interventional.bayer.com

Boston Scientific - www.bostonscientific.com

Covidien - www.turbohawkdevice.com

Cardiovascular Systems Inc. (CSI) - www.csi360.com

Spectranetics - www.spectranetics.com

Related Content

Feature | Business| April 28, 2016 | Dave Fornell
 
Technology | Stents Peripheral| April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Auris Surgical Robotics, acquisition, Hansen Medical
News | Robotic Systems| April 26, 2016
Auris Surgical Robotics Inc. and Hansen Medical Inc. announced that they have signed a definitive merger agreement...
Siemens Sensis Vibe, hemodyanamics system

Siemens released the Sensis Vibe hemodyanamics system at ACC.16. The newer system offers better integration of cath lab data into cath lab reports and the electronic medical record (EMR).

Feature | ACC| April 25, 2016 | Jon Brubaker, MBA, RCVT, Tom Watson, BS, RCVT, and Sabrina Newell MS, RCS
There were several trends seen in new cardiovascular technologies showcased on the expo floor at the 2016 American...
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
Boston Scientific, Fetch 2 aspiration catheter, Class 1 recall
News | Thrombectomy Devices| April 20, 2016
April 20, 2016 — Boston Scientific Corp. announced a U.S.
ischemic postconditioning, STEMI patients, clinical outcomes, ACC.16
News | Cath Lab| April 19, 2016
A large randomized controlled trial of ischemic postconditioning in patients who had experienced ST-segment elevation...
STEMI, delayed or deferred stent implantation, DANAMI-3-DEFER trial, ACC.16
News | Cath Lab| April 18, 2016
Delayed or deferred stent implantation in patients showed no clinical benefit in patients experiencing the deadliest...
ACR, American College of Radiology, MEDCAC, peripheral arterial disease, PAD, seniors
News | Peripheral Arterial Disease (PAD)| April 18, 2016
The American College of Radiology (ACR), as a member of a coalition of leading medical societies, provided peripheral...
FFR-CT, heartflow
Feature | CT Angiography (CTA)| April 15, 2016 | Jeff Zagoudis
Fractional flow reserve-computed tomography (FFR-CT) is still in the early stages of clinical implementation in the U
Overlay Init